结直肠肿瘤分子亚型与患者生存的关联:7项国际研究汇总分析
该研究汇总7项观察性研究共5010例结直肠癌患者,依据微卫星不稳定、CpG岛甲基化表型及KRAS、BRAF突变将肿瘤分为5种亚型,分析其与疾病特异性生存和总生存的关系。结果发现2型肿瘤患者疾病特异性生存显著短于4型,且非MSI-high肿瘤患者疾病特异性生存显著短于MSI-high者。
要点
- 2型结直肠肿瘤患者疾病特异性生存显著短于4型(HR 1.66)。
- 非MSI-high肿瘤患者疾病特异性生存显著短于MSI-high者(HR 0.42)。
- 分子亚型组合可能有助于判断结直肠癌患者预后。
核心结论
- 由4种常见肿瘤标志物组合定义的结直肠肿瘤亚型与生存时间差异相关,可能用于判断患者预后。
研究设计与样本
- 汇总7项观察性研究,共纳入5010例结直肠癌患者,所有研究均收集肿瘤MSI、CIMP及KRAS、BRAF突变信息。
主要发现
- 2型肿瘤患者疾病特异性生存显著短于4型患者(HR 1.66;95% CI 1.33-2.07),不受性别、年龄或诊断分期影响。
- 非MSI-high肿瘤患者疾病特异性生存显著短于MSI-high患者(HR 0.42;95% CI 0.27-0.64),不受其他肿瘤标志物、分期、性别或年龄影响。
关键数值与推荐
- 肿瘤按标志物分为5型:1型(MSI-high、CIMP阳性、BRAF突变且KRAS无突变)、2型(非MSI-high、CIMP阳性、BRAF突变且KRAS无突变)、3型(非MSI-high且非CIMP、KRAS突变且BRAF无突变)、4型(非MSI-high且非CIMP、BRAF与KRAS均无突变)、5型(MSI-high、非CIMP、BRAF与KRAS均无突变)。
临床怎么用
- 临床可考虑结合MSI、CIMP、KRAS和BRAF状态对结直肠癌进行分子分型,辅助预后评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The heterogeneity among colorectal tumors is probably due to differences in developmental pathways and might associate with patient survival times. We studied the relationship among markers of different subtypes of colorectal tumors and patient survival. METHODS: We pooled data from 7 observational studies, comprising 5010 patients with colorectal cancer. All the studies collected information on microsatellite instability (MSI), CpG island methylator phenotype (CIMP), and mutations in KRAS and BRAF in tumors. Tumors with complete marker data were classified as type 1 (MSI-high, CIMP-positive, with pathogenic mutations in BRAF but not KRAS), type 2 (not MSI-high, CIMP-positive, with pathogenic mutations in BRAF but not KRAS), type 3 (not MSI-high or CIMP, with pathogenic mutations in KRAS but not BRAF), type 4 (not MSI-high or CIMP, no pathogenic mutations in BRAF or KRAS), or type 5 (MSI-high, no CIMP, no pathogenic mutations in BRAF or KRAS). We used Cox regression to estimate hazard ratios (HR) and 95% confidence intervals (CIs) for associations of these subtypes and tumor markers with disease-specific survival (DSS) and overall survival times, adjusting for age, sex, stage at diagnosis, and study population. RESULTS: Patients with type 2 colorectal tumors had significantly shorter time of DSS than patients with type 4 tumors (HRDSS 1.66; 95% CI 1.33-2.07), regardless of sex, age, or stage at diagnosis. Patients without MSI-high tumors had significantly shorter time of DSS compared with patients with MSI-high tumors (HRDSS 0.42; 95% CI 0.27-0.64), regardless of other tumor markers or stage, or patient sex or age. CONCLUSIONS: In a pooled analysis of data from 7 observational studies of patients with colorectal cancer, we found that tumor subtypes, defined by combinations of 4 common tumor markers, were associated with differences in survival time. Colorectal tumor subtypes might therefore be used in determining patients' prognoses.
引用
- Phipps AI, Alwers E, Harrison T, et al. Association Between Molecular Subtypes of Colorectal Tumors and Patient Survival, Based on Pooled Analysis of 7 International Studies. Gastroenterology. 2020. PMID: 32088204. doi:10.1053/j.gastro.2020.02.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。